We actively engage in impactful, science-driven, non-competitive Public-Private Partnerships together with industry, academia and other public partners.
Using new technology, data, and tools, we build a better knowledge of disease and treatment areas. Together with our partners, we help improve healthcare systems for the benefit of patients and society.
On this page you can see more about our current partnerships and find out how you can connect with us to drive innovation and change.
Novo Nordisk is an active participant in the EU-anchored Innovative Health Initiative (IHI), formerly the Innovative Medicines Initiative (IMI) – the world’s largest Public-Private Partnership framework within health technology and life sciences.
For more than 10 years, Novo Nordisk has been a significant IHI contributor with direct involvement in over 40 diverse stakeholder projects, each with multi-million Euro budgets.
“We are very happy to have joined the IMI SOPHIA and work in partnership with Novo Nordisk. This fruitful collaboration offered the possibility for the Medical Informatics Platform, which currently serves multinational consortia to explore decentralised medical data in the field of brain diseases, to extend to the field of obesity.”
- From Prof. Philippe Ryvlin, Head of The Department of Clinical Neurosciences (DNC) at the Lausanne University Hospital (CHUV)